TEL AVIV, Israel, November 15, 2016 /PRNewswire/ --
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing
and developing promising therapeutic candidates, announced today
that it will release its unaudited financial results for the
quarter ended September 30, 2016, on
Tuesday, November 22, 2016, before
the U.S. markets open.
The Company will host a conference call on Tuesday, November 22, 2016 at 10:00 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer of
BioLineRx. The conference call will be available via webcast and
can be accessed through the Investor Relations section of
BioLineRx's website, http://www.biolinerx.com. Please allow extra
time prior to the call to visit the site and download any necessary
software to listen to the live broadcast.
To dial into the conference call, please dial 1-866-744-5399
from the U.S. or +972-3-918-0692 internationally. A replay of the
conference call will be available approximately two hours after
completion of the live conference call at http://www.biolinerx.com.
A dial-in replay of the call will be available until November 25, 2016; please dial 1-866-276-1485
from the U.S. or +972-3-925-5944 internationally.
About BioLineRx
BioLineRx is a clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds,
primarily from academic institutions and biotech companies based in
Israel, develops them through
pre-clinical and/or clinical stages, and then partners with
pharmaceutical companies for advanced clinical development and/or
commercialization.
BioLineRx's leading therapeutic candidates are: BL-8040, a
cancer therapy platform, which has successfully completed a Phase
2a study for relapsed/refractory AML, is in the midst of a Phase 2b
study as an AML consolidation treatment, and has recently initiated
a Phase 2 study in stem cell mobilization for allogeneic
transplantation; and BL-7010 for celiac disease and gluten
sensitivity, which has successfully completed a Phase 1/2 study. In
addition, BioLineRx has a strategic collaboration with Novartis for
the co-development of selected Israeli-sourced novel drug
candidates; a collaboration agreement with MSD (known as Merck in
the US and Canada) to run a Phase
2a study in pancreatic cancer using the combination of BL-8040 and
Merck's KEYTRUDA®; and has recently signed a
collaboration agreement with Genentech, a member of the Roche
Group, to investigate the combination of BL-8040 and Genentech's
Atezolizumab in several Phase 1b studies for multiple solid tumor
indications and AML.
For additional information on BioLineRx, please visit the
Company's website at http://www.biolinerx.com, where you can review
the Company's SEC filings, press releases, announcements and
events. BioLineRx industry updates are also regularly updated on
Facebook, Twitter, and LinkedIn.
Various statements in this release concerning
BioLineRx's future expectations constitute
"forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements include words such as
"may," "expects,"
"anticipates,"
"believes," and
"intends," and describe opinions about
future events. These forward-looking statements involve known and
unknown risks and uncertainties that may cause the actual results,
performance or achievements of BioLineRx to be materially different
from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks
are: changes in relationships with collaborators; the impact of
competitive products and technological changes; risks relating to
the development of new products; and the ability to implement
technological improvements. These and other factors are more fully
discussed in the "Risk Factors" section
of BioLineRx's most recent annual report on Form 20-F
filed with the Securities and Exchange Commission on March 10, 2016. In addition, any forward-looking
statements represent BioLineRx's views only as of the
date of this release and should not be relied upon as representing
its views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required
by law.
Contact:
PCG Advisory
Vivian Cervantes
Investor Relations
+1-212-554-5482
vivian@pcgadvisory.com
or
Tsipi Haitovsky
Public Relations
+972-3-624-0871
tsipihai5@gmail.com
SOURCE BioLineRx Ltd.